Reply to S. Fuji.
作者信息
Levis Mark J, Hamadani Mehdi, Horowitz Mary M, Chen Yi-Bin
机构信息
Mark J. Levis, MD, PhD, Johns Hopkins University, Baltimore, MD; Mehdi Hamadani, MD and Mary M. Horowitz, MD, CIBMTR / Medical College of Wisconsin, Milwaukee, WI; and Yi-Bin Chen, MD, Massachusetts General Hospital, Boston, MA.
出版信息
J Clin Oncol. 2024 Nov 10;42(32):3881-3882. doi: 10.1200/JCO.24.01091. Epub 2024 Jul 31.
Abstract
摘要
相似文献
1
Reply to S. Fuji.
J Clin Oncol. 2024 Nov 10;42(32):3881-3882. doi: 10.1200/JCO.24.01091. Epub 2024 Jul 31.
2
Reply to S. Fuji.
J Clin Oncol. 2020 Feb 10;38(5):523. doi: 10.1200/JCO.19.02689. Epub 2019 Dec 5.
3
Reply to S. Fuji.
J Clin Oncol. 2021 Apr 20;39(12):1412-1413. doi: 10.1200/JCO.20.02891. Epub 2021 Feb 23.
4
Comparison of the shear bond strength of 3D printed temporary bridges materials, on different types of resin cements and surface treatment.
J Clin Exp Dent. 2019 Apr 1;11(4):e367-e372. doi: 10.4317/jced.55617. eCollection 2019 Apr.
5
FTIR investigation of polymerisation and polyacid neutralisation kinetics in resin-modified glass-ionomer dental cements.
Biomaterials. 2002 Aug;23(15):3289-95. doi: 10.1016/s0142-9612(02)00092-3.
6
Physico-mechanical properties of a fast-set highly viscous GIC restorative.
J Oral Rehabil. 2003 Jan;30(1):1-8. doi: 10.1046/j.1365-2842.2003.01006.x.
7
Reply to S. Fuji et al.
J Clin Oncol. 2014 Jun 10;32(17):1860-1. doi: 10.1200/JCO.2014.55.4048. Epub 2014 May 5.
8
Comparative Evaluation of the Antimicrobial Properties of Glass Ionomer Cements with and without Chlorhexidine Gluconate.
Int J Clin Pediatr Dent. 2016 Apr-Jun;9(2):99-103. doi: 10.5005/jp-journals-10005-1342. Epub 2016 Jun 15.
9
Fluoride release by glass ionomer cements, compomer and giomer.
Dent Res J (Isfahan). 2009 Fall;6(2):75-81.
10
Genomic dissection of a 'Fuji' apple cultivar: re-sequencing, SNP marker development, definition of haplotypes, and QTL detection.
Breed Sci. 2016 Sep;66(4):499-515. doi: 10.1270/jsbbs.16018. Epub 2016 Jul 8.
本文引用的文献
1
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .
J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12.
2
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
J Clin Oncol. 2023 Sep 10;41(26):4236-4246. doi: 10.1200/JCO.22.02721. Epub 2023 Jun 28.
3
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
Clin Pharmacokinet. 2020 Oct;59(10):1273-1290. doi: 10.1007/s40262-020-00888-w.
Zotero 插件